Weekly administration of prophylactic tamoxifen is much less effective than the standard daily regimen in preventing the adverse breast effects induced by bicalutamide. Bicalutamide monotherapy is ...

Switching to an AI following 2–3 years of initial adjuvant tamoxifen is an effective option for patients unable to begin treatment with an AI. This article evaluates the most up-to-date results ...

MONDAY, Dec. 16, 2024 (HealthDay News) -- The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an early, low-risk form of breast ...